Cancer drug slows poxvirus in mice
...Abl, causes a rare form of cancer known as chronic myelogenous leukemia (CML). Gleevec inhibits Abl-family tyrosine kinases and has proved very useful in treating CML. To learn whether Gleevec could prevent or lessen vaccinia's ability to spread in a living organism, the researchers treated mice with either sal...New strategy rapidly identifies cancer targets
...c, which Druker pioneered for treatment of chronic myelogenous leukemia. Since its approval in 2001, Gleevec has made CML a much more manageable disease. A new drug to inhibit JAK3 is already in development elsewhere, and, eventually, Druker sees a market filled with a dozen or more tyrosine kinase inhibitors...'Tribbles' protein implicated in common and aggressive form of leukemia
...ave identified a new protein associated with acute myelogenous leukemia (AML). Several lines of evidence point to a protein called Tribbles, named after the furry creatures that took over the starship Enterprise in the original Star Trek series. Tribbles was first described in fruit flies. "Tribbles had neve......vec, which revolutionized the treatment of chronic myelogenous leukemia, is a so-called signal transduction inhibitor or STI, a small molecule that stifles inappropriate growth signals sent by mutant proteins in cancer cells. STIs may look like overnight successes, but they are actually the result of decades of ...GLEEVEC - An Oral treatment for leukemia
...cer. It is given as an oral treatment for chronic myelogenous leukemia (CML). Other molecular-targeting drugs previously approved by the FDA interfere with proteins associated with other cancers, but not with proteins that directly cause the disease. Gleevec, was discovered and developed by Novartis Oncol...GLEEVEC - An Oral treatment for leukemia
...cer. It is given as an oral treatment for chronic myelogenous leukemia (CML). Other molecular-targeting drugs previously approved by the FDA interfere with proteins associated with other cancers, but not with proteins that directly cause the disease. Gleevec, was discovered and developed by Novartis Oncol...Leukemia pill shows promise against stomach cancer
...c cases of GIST as it has been in treating chronic myelogenous leukemia (CML). Researchers reported 59 percent of patients with advanced-stage GIST went into remission and up to 75 percent showed some type of improvement with limited side effects. GIST accounts for about two percent of all abdominal cancers. I......ed the drug, Gleevec, for the treatment of chronic myelogenous leukemia, a form of cancer that affects about 4,500 people in the USA each year. A study supports Gleevec's image as a potential cure for this kind of cancer, which, although cases are rare, can be deadly. // A new study adds to the evidence suggest......a. A new study shows promising treatment for acute myelogenous leukemia // patients may lie in artificially stimulating natural killer cells from a patient’s family member. Researchers say this method could help treat patients with the highly fatal cancer of the bone marrow that has become resistant to standar...Cytokinetics Reports Additional Clinical Trials Data for Ispinesib
...with relapsed or refractory acuteleukemia, chronic myelogenous leukemia in blast crisis, or advancedmyelodysplastic syndromes. Data from this trial are expectedin 2007. Background on Mitotic Kinesin Inhibitors Since their introduction over 40 years ago, anti-mitotic drugs(taxanes and vinca alkaloids) have adv......al trial in a subset ofelderly patients with acute myelogenous leukemia (AML) or high-riskmyelodysplastic syndrom...s with previouslyuntreated de novo poor-risk acute myelogenous leukemia. Anadditional trial of Cloretazine(R) (VNP40101M) as a single agent insmall cell lung cance...Infinity and MedImmune Present Updated Phase I Results of IPI-504 in GIST at ASCO Annual Meeting
... receptor, (EGFR), in NSCLC,and Bcr-Abl in chronic myelogenous leukemia. Hsp90 enables thosecancers' survival by maintaining the function of oncogenic clientproteins. In preclinical studies, inhibition of Hsp90 has beenshown to lead to the degradation of these proteins and cell death,or apoptosis. In addition, o......ation of efficacy data in older patients withacute myelogenous leukemia (AML) and activity observed in patientswith refractory acute lymphocytic leukemia (ALL). Gliadel(R) Wafer(polifeprosan 20 with carmustine implant) was the subject of twoposters with one detailing the impact of multimodal therapy thatincluded...Clinical Data Reported on Vidaza in Hematologic Malignancies and Advanced Solid Tumors
...of patients, while transformation fromMDS to acute myelogenous leukemia (AML) occurs in up to 40 percentof patien...emia cellproliferation in some patients with acute myelogenous leukemia(AML). XL999 exhibited potent activity in preclinicaltarget-specific pharmacodynamic models,...